Ultragenyx Executive Vice President Sells $185K in Stock

Karah Herdman Parschauer, an EVP at the biopharmaceutical company, disposed of over 8,000 shares.

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

Karah Herdman Parschauer, an Executive Vice President at Ultragenyx Pharmaceutical, sold 8,135 shares of the company's stock on March 2nd. The shares were sold at an average price of $22.80, resulting in a total transaction value of $185,478. Following the sale, Parschauer still owns 76,346 shares of Ultragenyx, valued at approximately $1.74 million.

Why it matters

Insider transactions, such as this stock sale by a high-ranking Ultragenyx executive, can provide insights into a company's performance and the confidence of its leadership. While a single transaction does not necessarily indicate broader trends, it is noteworthy when a senior executive chooses to sell a significant portion of their holdings.

The details

Parschauer's sale represents a 9.63% decrease in her ownership stake in Ultragenyx. The biopharmaceutical company, focused on developing therapies for rare and ultra-rare genetic disorders, has seen its stock price fluctuate in recent months, closing at $21.80 on the day of the transaction.

  • The stock sale occurred on Monday, March 2, 2026.

The players

Karah Herdman Parschauer

An Executive Vice President at Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical

A biopharmaceutical company focused on developing therapies for rare and ultra-rare genetic disorders.

Got photos? Submit your photos here. ›

The takeaway

This transaction highlights the ongoing volatility in Ultragenyx's stock price and the potential shifts in confidence among the company's leadership. Investors will likely continue to monitor insider trading activity at Ultragenyx as an indicator of the company's performance and future prospects.